AJMC

Relationship Between High Cost Sharing and Adverse Outcomes: A Truism That’s Tough to Prove | Page 2

Published Online: April 07, 2010
Niteesh K. Choudhry, MD, PhD
It is a clear policy priority to understand the clinical and economic trade-offs associated with high patient cost sharing for essential medications. This is especially true as the level of cost sharing faced by commercially insured patients continues to increase,20 and the economy stagnates. While Philipson et al’s results are consistent with a large literature on this topic, their analysis highlights the challenges in quantifying a relationship that seems to be a truism.

Author Affiliations: From the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA.

 

Funding Source: None reported.

 

Author Disclosure: Dr Choudhry receives research funds from the Commonwealth Fund, the Robert Wood Johnson Foundation, and Aetna for work related to setting copayments for cardiovascular medications. He is a consultant to Mercer Health and Benefits, Inc.

 

Authorship Information: Concept and design; drafting of the manuscript; and critical revision of the manuscript for important intellectual content.

 

Address correspondence to: Niteesh K. Choudhry, MD, PhD, Brigham and Women’s Hospital, 1620 Tremont St, Ste 3030, Boston, MA 02120. E-mail: nchoudhry@partners.org.

 

1. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
2. Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med. 2008;23(2):216-218.
3. Choudhry NK. Copayment levels and medication adherence: less is more. Circulation. 2009;119(3):365-367.
4. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
5. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke. 2007;38(10):2652-2657.
6. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy  user effect. Am J Epidemiol. 2007;166(3):348-354.
7. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051-2057.
8. Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care. 2010;16(4):290-297.
9. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960-966.
10. Choudhry NK, Levin R, Avorn J. The economic consequences of non-evidence-based clopidogrel use. Am Heart J. 2008;155(5):904-909.
11. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006;166(7):806-811.
12. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [published correction appears in  N Engl J Med. 2006;354(7):778]. N Engl J Med. 2004;350(15):1495-1504.
13. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome [published correction appears in JAMA. 2008;299(20):2390]. JAMA. 2008;299(5):532-539.
14. Choudhry NK, Brennan T, Toscano M, et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008;156(1):31-36.
15. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation. 2008;118(18):1785-1792.
16. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-779.
17. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522.
18. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62(12):1226-1232.
19. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm  Ther. 2002;27(4):299-309.
20. Kaiser Family Foundation and Health Research and Educational Trust. Employer Health Benefits 2007 Annual Survey. http://www.kff.org/insurance/7672/index.cfm. Accessed January 31, 2008.

Issue: April 2010
More on AJMC.COM